The HIV-1 p24 ELISA Kit is a quantitative immunoassay designed to measure the core antigen p24 of the Human Immunodeficiency Virus type 1 (HIV-1).
This protein, encoded by the gag gene, forms the viral capsid, a structural shell surrounding the viral RNA genome. Because the p24 antigen appears early during infection—before antibodies are detectable—it serves as a critical marker for early HIV detection and viral replication monitoring in both clinical and research applications.

The Centers for Disease Control and Prevention (CDC) describes the p24 antigen as the key target in fourth-generation HIV tests, which detect both antigen and antibody to reduce the diagnostic window. (CDC.gov)

This kit also has broad research utility: it enables scientists to quantify HIV replication, validate lentiviral vector titers, and study viral protein expression during infection or gene therapy development.

Background: What is the HIV-1 p24 Antigen?

The p24 antigen is a 24 kDa capsid protein, part of the Gag polyprotein (Pr55-Gag), which is cleaved into several structural components: matrix (p17), capsid (p24), nucleocapsid (p7), and p6.
The p24 subunit forms the conical viral core, essential for virus assembly, maturation, and infectivity.

During viral replication, newly produced p24 is released into the bloodstream and can be detected by immunoassays long before anti-HIV antibodies are formed.
According to the National Institutes of Health (NIH), measuring p24 antigen levels is a powerful way to track viral load, disease progression, or treatment efficacy in controlled research settings.

The National Library of Medicine (NLM) includes thousands of peer-reviewed studies demonstrating that p24 detection correlates with viral RNA copies and is an essential metric in HIV pathogenesis studies and clinical virology.

Principle of the HIV-1 p24 ELISA Assay

The Enzyme-Linked Immunosorbent Assay (ELISA) is based on the antigen–antibody binding principle.
Most p24 ELISA kits use a sandwich format, in which the p24 antigen is captured between two antibodies:

1. Capture antibody (anti-p24 monoclonal) is pre-coated on the 96-well plate.

2. Sample (containing p24 antigen) binds to the immobilized antibody.

3. Detection antibody, also specific to p24, binds to another epitope on the same antigen.

4. Enzyme conjugate (HRP) is added, followed by substrate (TMB).

5. Optical density is measured at 450 nm, directly proportional to antigen concentration.

Protocols are standardized for sensitivity down to ~1 pg/mL, enabling accurate detection of trace antigen levels in serum, plasma, or cell culture supernatants.
For detailed methodology, see NIH Assay Development Resources.

The Importance of p24 Detection

 Early Infection Detection

The appearance of p24 precedes seroconversion by up to 10–15 days.
According to CDC HIV Laboratory Testing Guidelines, this reduces the window period significantly compared to antibody-only tests.

 Viral Load Correlation

Studies by the National Center for Biotechnology Information (NCBI) show a strong linear relationship between p24 antigen levels and plasma viral RNA concentration.
p24 quantification thus provides a cost-effective surrogate for viral RNA measurement in low-resource research environments.

 Lentiviral Vector Quantification

Gene-therapy production often relies on lentiviral vectors derived from HIV-1.
The p24 ELISA Kit enables vector titer quantification, a critical quality control step in production workflows.
The U.S. Food and Drug Administration (FDA) includes such antigen assays among the standard tools for viral vector characterization.

 Vaccine and Antiviral Research

In vaccine or drug development, p24 measurement helps monitor viral inhibition, immune response, and replication kinetics.
NIH-supported projects use p24 assays to evaluate the efficacy of vaccine candidates and antiretroviral compounds (NIH.gov).

Detailed Assay Workflow

Step 1: Sample Preparation

• Human serum or plasma: Centrifuge at 2000×g for 10 min, remove supernatant, and store at −80 °C.

• Cell culture supernatant: Filter or centrifuge to remove debris.

• If immune complexes are suspected (p24 bound to antibodies), perform acid dissociation (1 N HCl + neutralization buffer). (Abcam Protocol)

Step 2: Standard Curve

Reconstitute recombinant p24 antigen and prepare serial dilutions (1000 pg/mL → 4.7 pg/mL).
This ensures accurate interpolation of unknown sample concentrations.

Step 3: Assay Procedure

1. Add 100 µL standards and samples to pre-coated wells.

2. Incubate 1 hour at room temperature.

3. Wash wells (3–5 ×) with buffer to remove unbound material.

4. Add 100 µL HRP-conjugate detection antibody.

5. Incubate and wash again.

6. Add TMB substrate; after color development, stop reaction with acid stop solution.

7. Measure absorbance at 450 nm using a microplate reader.

Step 4: Data Analysis

• Plot standard curve (OD 450 nm vs. p24 pg/mL).

• Determine unknown sample concentrations by interpolation.

• Report results with sample ID, dilution, and batch information for traceability.

For standardized calculation models, refer to the National Institute of Standards and Technology (NIST).

Analytical Performance

Technical Considerations

• Sample quality strongly influences accuracy. Hemolysis or lipemia may interfere with optical readings. (CDC Biospecimen Quality Standards)

• Immune complex dissociation is critical for chronic samples; omitting this step can lead to underestimation.

• Temperature and incubation time must be consistent to ensure reproducibility.

• Proper calibration of microplate readers (450 nm) is essential for linear standard curves.

• Matrix effects (e.g., serum vs. plasma vs. cell supernatant) should be evaluated through spiked recovery tests.

Laboratories following NIH biosafety level 2 (BSL-2) guidelines must handle infectious materials in certified biosafety cabinets (NIH Biosafety Manual).

Advantages of Commercial HIV-1 p24 ELISA Kits

• High Sensitivity: Detects antigen concentrations as low as 1 pg/mL.

• Quantitative Measurement: Provides numerical data for viral load studies.

• Broad Sample Compatibility: Works with serum, plasma, and culture media.

• Standardization: Pre-coated wells and reagents ensure consistency.

• High Throughput: 96-well format supports parallel testing.

• Cost-Efficiency: Simpler and cheaper than RNA-based viral load assays.

• Automation Ready: Compatible with automated ELISA platforms.

Kits like the Abcam HIV-1 p24 ELISA Kit or the CellBioLabs Lentiviral p24 Assay demonstrate reproducible, validated performance in research laboratories worldwide.

Common Limitations

• Reduced sensitivity after seroconversion: Once antibodies bind p24, free antigen concentration drops.

• Matrix interference: Serum proteins or sample contaminants can inhibit binding.

• Not diagnostic unless FDA-approved: Research kits (RUO) must not be used for clinical diagnosis.

• Manual pipetting errors: ELISA precision requires careful handling.

• Storage stability: Components should be stored at 2–8 °C; repeated freeze-thaw cycles degrade antibodies.

The U.S. Environmental Protection Agency (EPA) provides guidelines for safe disposal of chemical reagents and biological waste from ELISA procedures.

Research and Biotechnology Applications

 HIV-1 Pathogenesis

Quantifying p24 enables researchers to monitor viral replication kinetics in in vitro cell cultures, PBMCs, and macrophage systems.
The NIH Office of AIDS Research funds studies that use p24 assays to understand viral replication cycles and immune evasion.

 Gene Therapy and Lentiviral Production

Gene therapy platforms using HIV-derived lentiviral vectors rely on p24 quantification for vector titration and batch consistency.
FDA and NIST recommend inclusion of p24 assays in vector release testing pipelines for potency assessment (FDA.gov).

 Vaccine and Antiviral Drug Development

In vaccine trials, reduction of p24 levels after immunization indicates neutralization activity or immune suppression of viral replication.
The ClinicalTrials.gov database lists multiple HIV vaccine trials using p24 ELISA endpoints.

 Diagnostic Algorithm Research

Fourth-generation HIV tests that include p24 detection shorten the diagnostic window.
The University of Washington HIV Curriculum describes p24’s role in diagnostic strategies.

 Educational and Training Use

In academic institutions such as Harvard University, p24 ELISA serves as a teaching model to explain antigen–antibody interactions, quantitative immunoassay principles, and biosafety practices.

Biosafety and Waste Management

• Follow BSL-2 containment for HIV-related materials (NIH Guidelines).

• Decontaminate liquid waste with 10 % bleach or autoclaving before disposal.

• Use biohazard labeling per OSHA laboratory safety rules.

• Store kit reagents separately from infectious materials.

• Dispose of used microplates following EPA hazardous waste guidelines (EPA.gov).

Example Product – Rapid-Lenti™ HIV-1 p24 ELISA Kit (Research Use Only)

• Detection Range: 4.7–1000 pg/mL

• Sample Types: cell culture supernatant, serum, plasma

• Assay Time: 3 hours

• Reproducibility: CV ≤ 10 %

• Application: Lentiviral vector quantification and HIV-1 p24 antigen analysis

Such kits are available from biotechnology suppliers like Affigen, Gentaur, and Abcam, offering standard protocols for both manual and automated ELISA systems.

Future Perspectives

The next generation of p24 assays is moving toward nanobody-based detection and electrochemical ELISA platforms, which further lower detection limits to femtogram levels.
Integration with microfluidic chips and biosensor systems allows real-time detection of HIV antigens from minimal sample volumes.
The U.S. Department of Energy (DOE) and NIH Innovation Programs support miniaturized diagnostic platforms for field use (Energy.gov, NIH.gov).

Conclusion

The HIV-1 p24 ELISA Kit remains a cornerstone assay in virology and biotechnology.
It provides a sensitive, quantitative, and cost-effective method for measuring the p24 core antigen in research samples — essential for early detection, viral load assessment, vaccine evaluation, and gene-therapy quality control.

By following standardized workflows and biosafety protocols, researchers can achieve reproducible and accurate results aligned with quality standards established by CDC, NIH, FDA, and NIST.

This assay bridges fundamental immunology with applied biotechnology, empowering scientists worldwide to better understand HIV biology, improve therapeutics, and advance diagnostic innovations.